Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Receptor May Help Spread of Alzheimer’s and Parkinson’s in Brain

By BiotechDaily International staff writers
Posted on 10 Sep 2013
Image: Electron micrograph shows clumps of corrupted tau protein outside a nerve cell. Scientists have identified a receptor that lets these clumps into the cell, where the corruption can spread. Blocking this receptor with drugs may help treat Alzheimer’s, Parkinson’s and other disorders (Photo courtesy of PNAS - Proceedings of the National Academy of Sciences of the United States of America).
Image: Electron micrograph shows clumps of corrupted tau protein outside a nerve cell. Scientists have identified a receptor that lets these clumps into the cell, where the corruption can spread. Blocking this receptor with drugs may help treat Alzheimer’s, Parkinson’s and other disorders (Photo courtesy of PNAS - Proceedings of the National Academy of Sciences of the United States of America).
Scientists have found the process in which corrupted, disease-causing proteins spread in the brain, potentially contributing to Alzheimer’s disease, Parkinson’s disease, and other brain-damaging disorders.

The research identifies a specific type of receptor and suggests that blocking it may help treat of these disorders. The receptors are called heparan sulfate proteoglycans (HSPGs). “Many of the enzymes that create HSPGs or otherwise help them function are good targets for drug treatments,” said senior author Marc I. Diamond, MD, a professor of neurology at the Washington University School of Medicine in St. Louis (MO, USA). “We ultimately should be able to hit these enzymes with drugs and potentially disrupt several neurodegenerative conditions.”

The study’s findings were published online August 2013 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). Over the 10 years, Dr. Diamond has gathered evidence that Alzheimer’s disease and other neurodegenerative disorders spread through the brain in a manner similar to conditions such as mad cow disease, which are caused by misfolded proteins known as prions.

Dr. Diamond and his colleagues have shown that a part of nerve cells’ inner structure known as tau protein can misfold into a formation called an amyloid. These corrupted versions of tau adhere to each other in clumps within the cells. Similar to prions, the clumps spread from one cell to another, seeding additional dispersal by causing copies of tau protein in the new cell to change into amyloids.

In the new study, first author Brandon Holmes, an MD/PhD student, demonstrated that HSPGs are necessary for binding, internalizing, and dispersing clumps of tau. When he genetically inactivated or chemically modified the HSPGs in cell cultures and in a mouse model, clumps of tau could not enter cells, thereby suppressing the spread of misfolded tau from cell to cell. Mr. Holmes also found that HSPGs are essential for the cell-to-cell spread of degraded forms of alpha-synuclein, a protein linked to Parkinson’s disease.

“This suggests that it may one day be possible to unify our understanding and treatment of two or more broad classes of neurodegenerative disease,” Dr. Diamond concluded. “We’re now sorting through about 15 genes to determine which are the most essential for HSPGs’ interaction with tau,” Mr. Holmes said. “That will tell us which proteins to target with new drug treatments.”

Related Links:
Washington University School of Medicine in St. Louis

comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.